Low-FODMAP Diet
A short-term diagnostic elimination diet developed for irritable bowel syndrome — not a general long-term eating plan.
What Is the Low-FODMAP Diet?
The low-FODMAP diet was developed by researchers at Monash University in Australia specifically to manage irritable bowel syndrome (IBS). FODMAP stands for Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols — short-chain carbohydrates found in foods like wheat, onions, garlic, certain fruits, dairy, and legumes. In sensitive individuals, these carbohydrates draw extra water into the gut and are rapidly fermented by gut bacteria, producing gas that can trigger bloating, pain, and altered bowel habits. Unlike most diets on this page, it's designed as a temporary diagnostic tool run in three structured phases, not an open-ended way of eating.
How It Works
Monash University describes the diet as three sequential phases, ideally supervised by a dietitian:
1. Elimination (2–6 weeks): high-FODMAP foods are swapped for low-FODMAP alternatives (an apple for an orange, rather than cutting out fruit entirely) until gut symptoms settle.
2. Reintroduction (roughly 6–8 weeks): each FODMAP subgroup — fructose, lactose, fructans, GOS, and polyols (sorbitol/mannitol) — is tested one at a time, a few days apart, while the rest of the diet stays low-FODMAP, to identify which specific subgroups trigger symptoms.
3. Personalization (ongoing): well-tolerated foods and FODMAP subgroups are added back long-term, and only the specific triggers identified in phase two are avoided — since tolerance can shift over time, occasional re-testing is part of the plan rather than permanent avoidance.
Read Monash University's phase breakdown →
The Evidence
The evidence for low-FODMAP specifically in IBS is genuinely strong and randomized — this is not a diet resting on observational data alone. But the size of the reported benefit varies by study and by how "improvement" is measured, so it's worth seeing the range rather than a single headline number.
Meta-analysis of randomized trials: Wang J, Yang P, Zhang L, Hou X. "A Low-FODMAP Diet Improves the Global Symptoms and Bowel Habits of Adult IBS Patients: A Systematic Review and Meta-Analysis," Frontiers in Nutrition, 2021. Pooling 10 randomized controlled trials (511 participants), global symptom improvement was significantly more likely on a low-FODMAP diet than on a control diet (risk ratio 1.54, 95% CI 1.18–2.00) — in the subset reporting responder rates, 60.8% of the low-FODMAP group improved versus 38.9% of controls.Read the meta-analysis →
On the often-cited "86%" figure: A widely repeated claim is that "up to 86% of IBS patients improve" on a low-FODMAP diet. That figure traces back to Nanayakkara WS, Skidmore PM, O'Brien L, Wilkinson TJ, Gearry RB. "Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date," Clinical and Experimental Gastroenterology, 2016 — a narrative review reporting that individual studies found response rates ranging from roughly 52% to 86%, not a single pooled result of 86%. The top of that range is a real, verifiable number from that review, but citing it alone without the 52% floor overstates the typical effect — the more rigorous pooled meta-analysis above (60.8% vs. 38.9%) is the better single figure to anchor on.
Read the 2016 review →
Effect on the gut microbiome: So D, Loughman A, Staudacher HM. "Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis," American Journal of Clinical Nutrition, 2022. Across 9 trials (403 patients), a low-FODMAP diet consistently lowered the abundance of Bifidobacteria, though it did not show a clear effect on overall microbial diversity or other specific bacterial groups — a real, if narrower, microbiome change than sometimes claimed.
Read the microbiome meta-analysis →
Who Should Be Cautious / Important Caveats
It's evidence-based for IBS, not for general "gut health." Every trial and meta-analysis above enrolled people already diagnosed with IBS or a related functional GI disorder. There is no comparable trial evidence supporting the low-FODMAP diet as a general wellness or "gut health" plan for people without a GI diagnosis — for that use case, the evidence is essentially absent rather than merely weak, and the restriction has no established benefit to offset its downsides.
It's meant to be short-term and reintroduced, not permanent. Monash University and clinical reviews consistently frame the elimination phase as temporary, followed by structured reintroduction. Staying on the elimination phase indefinitely — skipping reintroduction — is the pattern most guidance warns against.
Long-term, unsupervised restriction carries real risk. Prolonged low-FODMAP eating without reintroduction can reduce intake of nutrients like fiber, calcium, iron, and B vitamins (many of which come from high-FODMAP sources like wheat, dairy, and legumes), and — per the microbiome evidence above — can lower Bifidobacteria abundance. Cleveland Clinic's patient guidance explicitly frames it as not meant to be permanent, recommending a healthcare provider or registered dietitian monitor nutrition and deficiencies throughout.
Read Cleveland Clinic's guidance →
A diagnosis is what makes the restriction worth it. Without a GI condition the diet is meant to address, the diet asks for a meaningfully restrictive elimination phase in exchange for a benefit that hasn't been demonstrated. It's also not appropriate for anyone with a history of an eating disorder, and people already on restricted diets (vegan, multiple food allergies) or who are underweight or malnourished may struggle to meet nutrient needs during elimination.